Acadia Pharmaceuticals (ACAD) Revenue (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Revenue of $268.1 million for Q1 2026, up 9.72% year-over-year from $244.3 million in Q1 2025, and down 5.61% quarter-over-quarter from $284.0 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Revenue (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $268.1 million for Q1 2026.
- In Q1 2026, Revenue rose 9.72% year-over-year to $268.1 million; the TTM figure through Mar 2026 stood at $1.1 billion (up 9.93% YoY), while the FY2025 annual figure was $1.1 billion, up 11.87% from the prior year.
- Revenue for Q1 2026 stood at $268.1 million, down from $284.0 million in the prior quarter.
- The five-year high for Revenue was $284.0 million in Q4 2025, with the low at $115.5 million in Q1 2022.
- The 5-year median for Revenue is $231.0 million (2023), against an average of $208.3 million.
- The sharpest annual moves came in 2022 and 2024: Revenue retreated 0.68% in 2022, then jumped 73.75% in 2024.
- Acadia Pharmaceuticals' Revenue stood at $136.5 million in 2022, then surged by 69.27% to $231.0 million in 2023, then increased by 12.36% to $259.6 million in 2024, then grew by 9.39% to $284.0 million in 2025, then dropped by 5.61% to $268.1 million in 2026.
- Business Quant data shows ACAD's Revenue at $268.1 million in Q1 2026, $284.0 million in Q4 2025, and $278.6 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|